420 related articles for article (PubMed ID: 34387375)
1. Engineering Endogenous Tumor-Associated Macrophage-Targeted Biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo-Immunotherapy.
Wang Y; Yu J; Luo Z; Shi Q; Liu G; Wu F; Wang Z; Huang Y; Zhou D
Adv Mater; 2021 Oct; 33(39):e2103497. PubMed ID: 34387375
[TBL] [Abstract][Full Text] [Related]
2. Protein-Crowned Micelles for Targeted and Synergistic Tumor-Associated Macrophage Reprogramming to Enhance Cancer Treatment.
Sun JH; Liang X; Cai M; Yan L; Chen Z; Guo L; Jing L; Wang Y; Zhou D
Nano Lett; 2022 Jun; 22(11):4410-4420. PubMed ID: 35575719
[TBL] [Abstract][Full Text] [Related]
3. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
[No Abstract] [Full Text] [Related]
4. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
5. Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.
Xu HZ; Li TF; Wang C; Ma Y; Liu Y; Zheng MY; Liu ZJ; Chen JB; Li K; Sun SK; Komatsu N; Xu YH; Zhao L; Chen X
J Nanobiotechnology; 2021 Sep; 19(1):268. PubMed ID: 34488792
[TBL] [Abstract][Full Text] [Related]
6. Engineered Bacterial Biomimetic Vesicles Reprogram Tumor-Associated Macrophages and Remodel Tumor Microenvironment to Promote Innate and Adaptive Antitumor Immune Responses.
Zheng P; He J; Fu Y; Yang Y; Li S; Duan B; Yang Y; Hu Y; Yang Z; Wang M; Liu Q; Zheng X; Hua L; Li W; Li D; Ding Y; Yang X; Bai H; Long Q; Huang W; Ma Y
ACS Nano; 2024 Mar; 18(9):6863-6886. PubMed ID: 38386537
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 blockade restores CAR T cell activity through IFN-γ-regulation of CD163+ M2 macrophages.
Yamaguchi Y; Gibson J; Ou K; Lopez LS; Ng RH; Leggett N; Jonsson VD; Zarif JC; Lee PP; Wang X; Martinez C; Dorff TB; Forman SJ; Priceman SJ
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35738799
[TBL] [Abstract][Full Text] [Related]
8. Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy.
Zhu L; Li J; Guo Z; Kwok HF; Zhao Q
J Nanobiotechnology; 2022 Dec; 20(1):521. PubMed ID: 36496381
[TBL] [Abstract][Full Text] [Related]
9. In situ Engineering of Tumor-Associated Macrophages via a Nanodrug-Delivering-Drug (β-Elemene@Stanene) Strategy for Enhanced Cancer Chemo-Immunotherapy.
Chen W; Li Y; Liu C; Kang Y; Qin D; Chen S; Zhou J; Liu HJ; Ferdows BE; Patel DN; Huang X; Koo S; Kong N; Ji X; Cao Y; Tao W; Xie T
Angew Chem Int Ed Engl; 2023 Oct; 62(41):e202308413. PubMed ID: 37380606
[TBL] [Abstract][Full Text] [Related]
10. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
[TBL] [Abstract][Full Text] [Related]
11. Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy.
Wei X; Liu L; Li X; Wang Y; Guo X; Zhao J; Zhou S
J Control Release; 2019 Nov; 313():42-53. PubMed ID: 31629039
[TBL] [Abstract][Full Text] [Related]
12. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
[TBL] [Abstract][Full Text] [Related]
13. Multifunctional biomimetic nanoparticles loading baicalin for polarizing tumor-associated macrophages.
Han S; Wang W; Wang S; Wang S; Ju R; Pan Z; Yang T; Zhang G; Wang H; Wang L
Nanoscale; 2019 Nov; 11(42):20206-20220. PubMed ID: 31621735
[TBL] [Abstract][Full Text] [Related]
14. Plasmablastic Lymphomas: Characterization of Tumor Microenvironment Using CD163 and PD-1 Immunohistochemistry.
Ahn JS; Al-Habib A; Vos JA; Sohani AR; Barboza-Quintana O; Flores JP; Wen S; Rosado FG
Ann Clin Lab Sci; 2020 Mar; 50(2):213-218. PubMed ID: 32366559
[TBL] [Abstract][Full Text] [Related]
15. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
16. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
17. The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure.
Lima L; Oliveira D; Tavares A; Amaro T; Cruz R; Oliveira MJ; Ferreira JA; Santos L
Urol Oncol; 2014 May; 32(4):449-57. PubMed ID: 24252833
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant Chemotherapy Induces IL34 Signaling and Promotes Chemoresistance via Tumor-Associated Macrophage Polarization in Esophageal Squamous Cell Carcinoma.
Nakajima S; Mimura K; Saito K; Thar Min AK; Endo E; Yamada L; Kase K; Yamauchi N; Matsumoto T; Nakano H; Kanke Y; Okayama H; Saito M; Neupane P; Saze Z; Watanabe Y; Hanayama H; Hayase S; Kaneta A; Momma T; Ohki S; Ohira H; Kono K
Mol Cancer Res; 2021 Jun; 19(6):1085-1095. PubMed ID: 33674443
[TBL] [Abstract][Full Text] [Related]
19. Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells That Can Be Reprogrammed with Folate-Targeted Drugs.
Cresswell GM; Wang B; Kischuk EM; Broman MM; Alfar RA; Vickman RE; Dimitrov DS; Kularatne SA; Sundaram CP; Singhal S; Eruslanov EB; Crist SA; Elzey BD; Ratliff TL; Low PS
Cancer Res; 2021 Feb; 81(3):671-684. PubMed ID: 33203700
[TBL] [Abstract][Full Text] [Related]
20. Charge reversal yolk-shell liposome co-loaded JQ1 and doxorubicin with high drug loading and optimal ratio for synergistically enhanced tumor chemo-immunotherapy via blockade PD-L1 pathway.
Liu D; Li K; Gong L; Fu L; Yang D
Int J Pharm; 2023 Mar; 635():122728. PubMed ID: 36796659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
